Inhibikase Therapeutics, Inc. (IKT)

NASDAQ

$1.66

$-0.15

(-8.29%)

Inhibikase Therapeutics, Inc. (IKT) Live Price Chart

Page last updated: 2026-04-21 16:35:00

Key Market Data

Market Cap	$218.51M
Open	$1.79
High	$70.80
Low	$0.79
Previous Close	$1.81
Price Change	$-0.15
Percentage Change	-8.29%
Volume	1M

Inhibikase Therapeutics, Inc. (IKT) Stock Price Today

Inhibikase Therapeutics, Inc. (IKT) is currently trading at $1.66 as of 2026-04-21 16:35:00, reflecting a -8.29% move ($-0.15) from the previous close.

In the short term, the stock has returned -4.89% over the past four weeks. Over the last 12 months, Inhibikase Therapeutics, Inc. has recorded a -12.43% price change, indicating a Weak performance relative to the broader market.

Inhibikase Therapeutics, Inc. (IKT) 7-Day Stock Price Changes

Over the past seven days, Inhibikase Therapeutics, Inc. has traded within a short-term range shaped by market sentiment in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. During this period, the stock moved from its previous closing price of $1.69 to the latest recorded price of $1.66, reflecting an intraday change of -8.29%. Daily movements highlight shifts in trading volume (1,131,804), investor positioning, and reactions to macroeconomic updates.

From a momentum standpoint, IKT has delivered a -4.89% return over the past month and a -12.43% change in the last 12 months, indicating a Weak trend relative to its broader sector peers.

How to Buy Inhibikase Therapeutics, Inc. (IKT)

You can buy and trade IKT on MEXC in three simple steps:

Step 1: Create and Verify Your MEXC Account

Sign up on MEXC and complete the required identity verification (KYC). This ensures full access to trading features and secure funding options.

Step 2: Deposit Funds Into Your Account

Choose your preferred payment method to add USDT or other supported assets to your MEXC wallet. Depositing crypto is the fastest way to get started.

Step 3: Search for IKT and Execute Your Trade

Open the trading page, enter IKT in the search bar, select the amount of IKT you would like to purchase. Place a market order for instant execution or a limit order to buy at your target price.

What is Inhibikase Therapeutics, Inc. (IKT)?

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Inhibikase Therapeutics, Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	35
Sector	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Website	https://www.inhibikase.com

Frequently Asked Questions (FAQ)

1.What is the current share price of Inhibikase Therapeutics, Inc.?

The latest trading price for Inhibikase Therapeutics, Inc. (Common Stock) is $ 1.66, compared with a previous closing price of $ 1.81. That means the stock has moved -8.29% so far today. Intraday price updates and recent trading activity for IKT can be tracked on the live chart and quote section on this page.

2.Is Inhibikase Therapeutics, Inc. stock going up or down?

Looking at recent performances, IKT has returned -4.89% over the past month, +7.47% over the last six months and -12.43% over the past year. These figures capture share-price changes only, not the impact of dividends. Together they describe Weak price momentum for Inhibikase Therapeutics, Inc. stock, but keep in mind that past returns do not guarantee future results.

3.Where does IKT currently sit relative to its 52-week high and low?

In the most recent 52-week period, Inhibikase Therapeutics, Inc. has traded between a low of $ 1.33 and a high of $ 2.37. This 52-week range helps show where today's share price sits relative to its recent highs and lows, and is often used by investors to judge stock volatility, potential support and resistance levels, and whether IKT is currently nearer the top or the bottom of its one-year trading band.

4.How is Inhibikase Therapeutics, Inc. classified by sector and industry?

Inhibikase Therapeutics, Inc. is classified in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. In practice, this means Inhibikase Therapeutics, Inc. is grouped with other companies that serve similar end-markets and operate under comparable competitive and regulatory conditions. For investors, knowing IKT’s sector helps with portfolio diversification, peer comparisons, and understanding how broader trends affecting the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector could influence Inhibikase Therapeutics, Inc.’s performance.

5.Where is Inhibikase Therapeutics, Inc. listed and how large is it by market value?

Inhibikase Therapeutics, Inc. is listed on the NASDAQ stock exchange in United States. Based on a market capitalization of $ 218.51M, the company is classified as a Small-cap stock. Market cap gives a quick sense of Inhibikase Therapeutics, Inc.'s size and importance in the equity market and is often used by investors and index providers when constructing portfolios or benchmarks.

6.What does IKT's EPS tell investors about its profitability?

Trailing-twelve-month EPS of $ -0.37 summarises how much profit Inhibikase Therapeutics, Inc. has generated per share over the last year. Rising EPS over time can signal improving profitability or effective share repurchases, while flat or declining EPS may point to slower growth or margin pressure. EPS is a key input into valuation metrics such as P/E and is often monitored closely around earnings announcements.

7.How can I track Inhibikase Therapeutics, Inc.'s financial performance over time?

To follow Inhibikase Therapeutics, Inc.'s financial performance, investors typically review its quarterly and annual reports, which include detailed income statements, balance sheets and cash-flow statements. Combining these filings with key market data shown on this page—such as share price trends, P/E and dividend yield—provides a more complete view of how IKT is performing and how the market is responding.

8.When is Inhibikase Therapeutics, Inc. expected to report earnings?

Inhibikase Therapeutics, Inc.'s next scheduled earnings release is currently expected on -- (the date may be updated by the company). Earnings announcements often act as important catalysts for IKT, as they provide updated information on revenue, profitability and management's outlook.

9.What usually comes out in Inhibikase Therapeutics, Inc.'s earnings reports?

Inhibikase Therapeutics, Inc.'s earnings reports typically include headline figures such as revenue, net income and EPS, along with commentary on segment performance, margins, cash flow and guidance for future periods. Investors compare these results with market expectations and prior periods to assess whether IKT is meeting, beating or missing expectations.

10.How can I stay informed about Inhibikase Therapeutics, Inc.'s results and guidance?

You can stay up to date on Inhibikase Therapeutics, Inc. by reviewing its quarterly earnings releases, listening to or reading transcripts of earnings calls, and following company news and filings. Pairing this fundamental information with the price and return data for IKT on this page helps you see how new information is being reflected in the stock.

11.Does Inhibikase Therapeutics, Inc. pay a regular cash dividend to its shareholders?

Inhibikase Therapeutics, Inc. Non-paying. Based on the latest information, the stock has an indicated annual cash dividend of -- per share and a current dividend yield of 0 at the recent share price. Dividends are typically paid --, although the board can change the dividend policy at any time. Income-focused investors often monitor IKT's dividend level, payment frequency and any announcements about future dividends when assessing the stock's appeal as a dividend-paying investment.

12.What are the current dividend yield and dividend payout ratio for IKT?

Based on the latest earnings data, IKT has a dividend yield of 0 and a dividend payout ratio of 0. The dividend yield shows how much cash return an investor receives from dividends each year relative to the current share price, helping assess whether Inhibikase Therapeutics, Inc. is an attractive income stock. The dividend payout ratio measures what percentage of earnings Inhibikase Therapeutics, Inc. distributes to shareholders as dividends versus how much it retains to reinvest in the business, which is an important indicator of dividend sustainability and room for future dividend growth.

13.What kind of business is Inhibikase Therapeutics, Inc.?

Inhibikase Therapeutics, Inc. is a publicly traded company in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry within the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. It generates revenue from products and services related to this core business area, and investors can find a detailed description of its operations, strategy and geographic exposure in the company's annual report and other regulatory filings.

14.How is IKT valued in terms of P/E ratio and EPS?

Inhibikase Therapeutics, Inc. currently trades at a price-to-earnings (P/E) ratio of --, based on trailing-twelve-month earnings per share (EPS) of $ -0.37. P/E is calculated by dividing the share price by EPS and shows how much investors are paying today for each unit of Inhibikase Therapeutics, Inc.'s earnings. Comparing IKT's P/E and EPS to those of other BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) companies can help investors judge whether its valuation looks rich or attractive.

Explore More US Stocks

Largest Market Cap

See US stocks with the highest market capitalization

Most Actively Traded

Discover today's most actively traded US stocks

Barrick Mining Corporation

STE

CPA

Dream Finders Homes, Inc.

DFH

Top Gainers

Browse today's leading gainers in the US stock market

Electro-Sensors Inc.

ELSE

Faraday Future Intelligent Electric Inc.

FFAI

Local Bounti Corporation

LOCL

Republic Power Group Limited

RPGL

Dreamland Limited

TDIC

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

BTC

ETH

SOL

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

IKT-to-USD Calculator

Amount

IKT

USD

1 IKT = 1.655 USD